Vanguard reports 0 shares of NeoGenomics
NeoGenomics Inc Schedule 13G/A amendment: The Vanguard Group reports 0 shares beneficially owned of NeoGenomics common stock following an internal realignment.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
NeoGenomics Inc Schedule 13G/A amendment: The Vanguard Group reports 0 shares beneficially owned of NeoGenomics common stock following an internal realignment.
The filing explains subsidiaries and business divisions of The Vanguard Group now report separately in reliance on SEC Release No. 34-39538, and Vanguard states it holds 0% of the class.
Insights
Vanguard disaggregated holdings; Vanguard reports no beneficial ownership in NeoGenomics.
The amendment states The Vanguard Group underwent an internal realignment and that certain subsidiaries will report holdings separately in reliance on SEC Release No. 34-39538. The filing records 0 shares and 0% ownership of NeoGenomics common stock.
Cash‑flow treatment and specific subsidiary counts are not included in the excerpt; subsequent separate filings by Vanguard affiliates may show redistributed positions.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did The Vanguard Group report for NEO in this Schedule 13G/A?
Why does Vanguard say it now reports holdings separately for NEO?
Who signed the Schedule 13G/A amendment for Vanguard on NEO?
AI-generated analysis. How Rhea-AI works. Not financial advice.